Commercial Novo hits back at rivals with cut-price Wegovy subscriptions PharmaphorumTrying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.CommercialMetabolic & GLP-1Read full story pharminent March 31, 2026 (Last updated: April 1, 2026) Pharmaphorum Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers. CommercialMetabolic & GLP-1Read full story Post navigation Previous: Lilly beefs up neuroscience pipeline with $6.3B Centessa buyoutNext: S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026